25 3 31 1

1 2 0 5 3

2 0

5 0

0 13 0

0 0

0 4

33

H11.10.1 H19.3.31 H19.4.1 H22.6.30 H22.7.1

H8.8.1 H19.3.31 H19.4.1 H22.12.31 H23.1.1

H20.6.1 H23.1.31 23.2.1

H18.10.1 H19.3.31 H19.4.1 H24.3.31 H24.4.1

H18.4.1 H18.10.1 H19.12.16

H18.4.1 H19.3.31 H19.4.1 H20.1.15 ; H21.10.1~H23.3.31

; H23.4.1

H24.4.1

H23.4.1

H23.6.1

H23.4.1 H24.5.31

H24.6.1

H24.4.1

24

19 0

54.36

184

2

0.00

25 18

11.68

14 14

7 0

16.5

1. Konishi T, Kono S, Fujimoto M, Terada T, Matsushita K, Ouchi Y, Miyajima H:Benign hereditary

chorea: dopaminergic brain imaging in patients with a novel intronic NKX2.1 gene mutation, J Neurol,

260(1):207-13, 2013.

2. Sugimoto M, Watada M, Jung SW, Graham DY, Yamaoka Y:Role of Helicobacter pylori plasticity

region genes for development of gastroduodenal diseases, J Clin Microbiol, 50:441-448, 2012 .

3. Sugimoto M, Nishino M, Kodaira C, Yamade M, Uotani T, Ikuma M, Furuta T:Impact of acid inhibition

on esophageal mucosal injury induced by low-dose aspirin. Digestion, 85:9-17, 2012.

4. Sugimoto M, Shirai N, Nishino M, Kodaira C, Uotani T, Yamade M, Sahara S, Ichikawa H, Sugimoto K,

Miyajima H, Furuta T:Rabeprazole 10mg qds deceases 24-hour intragastric acidity significantly more

than rabeprazole 20mg bd or 40mg om overcoming CYP2C19 genotype, Aliment Pharmacol Ther,

36:627-634, 2012.

5. Kodaira C, Uchida S, Yamade M, Nishino M, Ikuma M, Namiki N, Sugimoto M, Watanabe H, Hishida

A, Furuta T:Influence of different proton pump inhibitors on activity of cytochrome P450 assessed by

[13C]-aminopyrine breath test, J Clin Pharmacol, 52:432-439, 2012.

6. Yamade M, Sugimoto M, Nishino M, Uotani T, Sahara S, Iwaizumi M, Yamada T, Osawa S, Sugimoto

K, Miyajima H, Furuta T:Trastuzumab Has Opposing Effects on SN-38-induced Double-strand Breaks

and Cytotoxicity in HER2-positive Gastric Cancer Cells Depending on Administration Sequence,

Anticancer Res, 32:105-112, 2012.

7. Takayanagi Y, Osawa S, Ikuma M, Takagaki K, Zhang J, Hamaya Y, Yamada T, Sugimoto M, Furuta T,

Miyajima H, Sugimoto K:Norepinephrine suppresses IFN- and TNF- production by murine intestinal

intraepithelial lymphocytes via the (1) adrenoceptor, J Neuroimmunol, 245:66-74, 2012.

8. Uotani T, Sugimoto M, Nishino M, Kodaira C, Yamade M, Sahara S, Yamada T, Osawa S, Sugimoto K,

Tanaka T, Umemura K, Watanabe H, Miyajima H, Furuta T: Ability of Rabeprazole to Prevent Gastric

Mucosal Damage from Clopidogrel and Low Doses of Aspirin Depends on CYP2C19 Genotype, Clin

185

Gastroenterol Hepatol, 10: 879-885, 2012.

9. Sahara S, Sugimoto M, Vilaichone RK, Mahachai V, Miyajima H, Furuta T, Yamaoka Y:Role of

Helicobacter pylori cagA EPIYA motif and vacA genotypes for the development of gastrointestinal

diseases in Southeast Asian countries: a meta-analysis, BMC Infect Dis, 12:223, 2012.

10. Zhang J, Osawa S, Takayanagi Y, Ikuma M, Yamada T, Sugimoto M, Furuta T, Miyajima H, Sugimoto

K: Statins directly suppress cytokine production in murine intraepithelial lymphocytes, Cytokine,

61:540-545, 2013.

11. Ohashi N, Tsuji N, Naito Y, Iwakura T, Isobe S, Ono M, Fujikura T, Tsuji T, Sakao Y, Yasuda H,

Kawamura K, Sakaguchi T, Kato A, Fujigaki Y:Relationship between urinary fractional excretion of

sodium and life prognosis in liver cirrhosis patients. Hepatol Res. 2013 Jan 14. doi: 10.1111/hepr.12068

35.01

1. Suzuki S, Fukasawa H, Misaki T, Togawa A, Ohashi N, Kitagawa K, Kotake Y, Liu N, Niida H,

Nakayama K, Nakayama KI, Yamamoto T, Kitagawa M:The amelioration of renal damage in

Skp2-deficient mice canceled by p27 Kip1 deficiency in Skp2-/- p27-/- mice, PLoS One, 7: e36249,

2012.

2. Hamaya Y, Kuriyama S, Takai T, Yoshida K, Yamada T, Sugimoto M, Osawa S, Sugimoto K, Miyajima

H, Kanaoka S:A Distinct Expression Pattern of the Long 30-Untranslated Region Dicer mRNA and Its

Implications for Posttranscriptional Regulation in Colorectal Cancer, Clinl Translational

Gastroenterology , 3:e17, 2012.

3. Kato A, Takita T, Furuhashi M, Maruyama Y, Miyajima H, Kumagai H: Brachial-ankle pulse wave

velocity and the cardio-ankle vascular index as a predictor of cardiovascular outcomes in patients on

regular hemodialysis, Ther Apher Dial, 16(3): 232-241, 2012.

4. Kato A, Takita T, Furuhashi M, Fujimoto T, Suzuki H, Maruyama Y, Sakao Y, Miyajima H:Association

of HCV core antigen seropositivity with long-term mortality in patients on regular hemodialysis,

Nephron Extra, 2(1): 76-86, 2012. 5.48

1. Shimatani T, Sugimoto M, Nishino M, Adachi K, Furuta K, Ito M, Kurosawa S, Manabe N, Mannen K,

Hongo M, Chiba T, Kinoshita Y:Predicting the efficacy of proton pump inhibitors in patients with

non-erosive reflux disease before therapy using dualchannel 24-h esophageal pH monitoring, J

186

Gastroenterol Hepetol, 27:899-906, 2012.

2. Jung SW, Sugimoto M, Shiota S, Graham DY, Yamaoka Y:The intact dupA cluster-forming type IV

secretion system is a more reliable Helicobacter pylori virulence marker than dupA alone, Infect Immun,

80:381-387, 2012.

3. Huang Y, Yamamoto T, Misaki T, Suzuki H, Togawa A, Ohashi N, Fukasawa H, Fujigaki Y, Ichihara A,

Nishiyama A, Senbonmatsu T, Ikegaya N, Hishida A:Enhanced intrarenal receptor-mediated prorenin

activation in chronic progressive anti-thymocyte serum nephritis rats on high salt intake, Am J Physiol

Renal Physiol, 303:F130-138, 2012.

4. Hanai H, Iida T, Takeuchi K, Arai H, Arai O, Abe J, Tanaka T, Maruyama Y, Ikeya K, Sugimoto K,

Nakamura T, Nakamura K, Watanabe F:Nutritional therapy versus 6-mercaptopurine as maintenance

therapy in patients with Crohn's disease, Dig Liver Dis, 44(8):649-54, 2012.

13.87

1. Ohashi N, Sakao Y, Fujikura T, Yasuda Y, Kato A, Fujigaki Y:Relationship between urinary fractional

excretion of sodium and life prognosis in liver cirrhosis patients, J Am Soc Nephrol, 23:903A, 2012.

1. Kato A, Sakao Y, Tsuji T, Ohashi N, Yasuda H, Fujigaki Y:Arterial Stiffening is related to changes in

body composition in patients on regular hemodialysis, J Am Soc Nephrol, 23:774A , 2012.

1. Kono S:Aceruloplasminemia, Curr Drug Targets, 13(9):1190-9, 2012.

2. , : , , 109:992-993, 2012.

3. Sugimoto M, Yamaoka Y, Shirai N, Furuta T:The role of the renin-angiotensin system in gastric

oncogenesis, J Gastroenterol Hepetol, 27:442-451, 2012.

4. Sugimoto M, Furuta T:Efficacy of Esomeprazole in treating acid-related diseases in Japanese

populations: A review, Clil Experimental Gastroenterol, 5:49-59, 2012.

5. Sugimoto M, Jang JS, Yoshizawa Y, Osawa S, Sugimoto K, Sato Y, Furuta T:Proton pump inhibitor

therapy before and after endoscopic submucosal dissection: A review, Diag Ther Endoscopy, 1-11,

2012.

6. , , , , , : GERD

, 21:445-452, 2012.

187

7. , , , , , :

, , 15:129-136, 2012.

8. , , , , , , , :

, Therapeutic Research, 33:293-301, 2012.

9. , , : Helicobacter

pylori , , 55:287-291, 2012.

10. , , : pH

, , 243:945-951, 2012.

11. Ohashi N, Sakao Y, Yasuda H, Kato A, Fujigaki Y:Methoxy polyethyleneglycol-epoetin beta for

anemia with chronic kidney disease, Int J Nephrol Renovasc Dis, 5:53-60, 2012.

12. Miyajima H:Editorial: neurodegeneration with brain iron accumulation. Curr Drug Targets 13(9):1181,

2012.

13. , , 43(2):123-124, 2012.

14. , , 44(6): 5-7, 2012.

15. , , 29(2):155-159, 2012.

16. , , Wernicke Thiamine transporter gene mutation I

Vitamin B1 , , 76(3): 248-254, 2012.

17. B1 .

Wernicke , Vitamins (Japan), 86(11): 625-629, 2012.

18. , :ALS2(alsin). II ALS, , 76(5): 472-476,

2012.

19. , : 1 2012-13,

,72 , 597-601, 2012.

20. , :AKI , AKI Q A, • , 24:

298- 303, 2012.

21. , : , ,

19:17-18, 2013.

22. : • 2

, Nutrition Care, 72-75,2012

23. : • 3

, Nutrition Care, 168-173,2012

9.97

1. Furuta T, Sugimoto M, Shirai N:Individualized Therapy for Gastrointestinal Reflux Disease: Potential

Impact of Pharmacogenetic Testing based on CYP2C19, Mol Diag Ther, 16:223-234, 2012.

188

2. , :

, 28:1695-1700, 2012.

1.71

1. , : AKI ,

AKI , Q A , , 97-98, 2012.

2. , :

, Q A , , 97-98, 2012.

3. :

AKI Q A , 88-90, 2012.

4. : AKI AKI

, , 134-141, 2012

5. :AKI ARF , Medical Practice , , , 685 , 2012.

6. , , , , 25-32,

2012.

7. , : , , , , ,

, Annual Review 2013 , , , 196-203, 2012.

8. , : , , , , , ,

, 2 , , , 752-757, 2012.

9. 2 , , ,

3 , , , 226-244, 2012.

10. , 13.

, 131-135.

11. : , , ,

2012-2014, , 366-369, 2012.

12. , : .

. C , , 179-191,

2012.

13. : , ,

, , 322-325, 2012.

14. :Wernicke , ,

, , 326-329, 2012.

189

1. Kono S, Bunai T, Terada T, Shimoyama K, Konishi T, Shirakawa K, Miyajima H:Subacute progressive

ophthalmoplegia associated with dermatomyositis, J Neurol, 259(9):1982-1984, 2012.

2. Kono S, Ouchi Y, Terada T, Suzuki M, Yagi S, Miyajima H: Combined FDG and raclopride PET study

in a case of ALS with the R521C FUS gene mutation, J Neurol, 259(2): 367-369, 2012.

3. Terai T, Sugimoto M, Uozaki H, Kitagawa T, Kinoshita M, Baba S, Yamada T, Osawa S, Sugimoto

K:Lymphomatoidgastropathy mimicking extranodal NK/T cell lymphoma, nasal type: a case report,

World J Gastroenterol, 18:2140-2144, 2112.

4. Ikeya K, Osawa S, Kuriyama S, Hamaya S, Yamada T, Sugimoto M, Furuta T, Sugimoto

K:Decompression side tube-equipped double-balloon enteroscopy extends intubation depth and reduces

patient discomfort, Endoscopy , 44 supple 2:E256-7, 2012.

5. Iwakura T, Fujigaki Y, Matsuyama T, Fujikura T, Ohashi N, Yasuda H, Kato A, Baba

S:Tubulointerstitial Nephritis and Primary Biliary Cirrhosis with a T Cell-dominant Profile of

Infiltrating Cells and Granulomas in Both Organs, Intern Med, 52: 467-471, 2013.

15.56

1. Uyama S, Ohashi N, Iwakura T, Ono M, Fujikura T, Sakao Y, Yasuda H, Kato A, Fujigaki Y:A case

presenting with the possible relationship between myeloperoxidase-antineutrophil cytoplasmic

antibody-associated glomerulonephritis and membranous changes of glomerular basement membrane,

CEN Case Rep DOI 10.1007/s13730-012-0039-9.

2. Miwa M, Sakao Y, Ishigaki S, Ono M, Fujikura T, Yasuda H, Suzuki H, Kato A, Nagata Y, Shigeno K,

Nakamura S, Ohnishi K, Fujigaki Y:Recovery of kidney function by rituximab-based therapy in a

patient with Waldenstrom's macroglobulinemia-related nephropathy presenting cast nephropathy and

interstitial lymphocytic infiltration, Intern Med, 51(13):1725-30, 2012.

0.94

24

0

24

6 630

190

3 230

0 0

3 500

12 500

29 1500

1. C :

, 22 24 , 230 24 80

2. B : MRI

, 22 24 , 480 24 60

3. C : SLC19A3

22 24 430 24 50

4. C :

23 24 24 180

5. C :

23 24 24 70

6. C :

24 26 483 24

190

1. : , ( /

, 24 , , 20

,

2. : , CKD

, 24 , , 10

,

3. : CKD

24 200

,

1. 22

, 22 24 , 200

2.

24 , 24

25 , , 200

3. (RAS)

191

24 25 , 100

12 500

0 1

0 13

0 3

0 1

0 24

11

1

2

3

4

5

1. Sugimoto M:The new trend of H. pylori eradication treatments including third-line therapy,

sequential therapy and concomitant therapy in Japan, 18 ,

, 2012 6 , ( )

1. Sugimoto M:Efficacy of frequent PPI dosing for potent acid inhibition over 24 hours,

, 2012 5 , San Diego( )

2. Sugimoto M:Antiplatelet drugs are a risk factor for esophageal mucosal injury, APDW, 2012 12

,

3. Konishi T:Genetic features and dopaminergic imaging in benign hereditary chorea, Meeting Of

European Neurological Society, 2012 9 , ( )

4. Yamada T:Guggulsterone, a plant sterol inhibitor of NF- B, suppresses CDX2 and COX-2

overexpression and reduces proliferation of esophageal adenocarcinoma cells, ,

2012 5 , ( )

5. Yamade M: Trastuzumab has opposing effects on SN-38-induced double strand breaks and

192

cytotoxicity in HER2-positive gastric cancer cells depending on administration sequence,

, 2012 5 , San Diego( )

6. Uotani T: Role of clopidogrel and rabeprazole in low-dose aspirin-induced gastric mucosal injury in

relation to CYP2C19 genotype, , 2012 5 , San Diego( ), Poster of

Distinction

7. Uotani T: The role of rabeprazole and famotidine for low-dose aspirin-induced gastric mucosal

injury with clopidogrel, APDW, 2012 12 , ( )

8. Sahara S: Association of Helicobacter pylori-related gastroduodenal diseases with vacA and cagA

genotypes in Southeast Asia, , 2012 5 , San Diego( )

9. Sahara S: Role of Helicobacter pylori cagA EPIYA motif and vacA genotypes for peptic ulcer in the

Southeast Asia, APDW, 2012 12 , ( )

10. Tsuji T: Partial recovery from AKI, followed by sepsis, worsens kidney injury and mortality, bur

protects other organs, ASN Kidney Week, 2012 11 , San Diego( )

1

1. 217 2012 6 16

2

1. =

=, 5 , , 2012 8 4

3

1. . 36 ,

1, , 2012 9 1

2. , 98

, 2012 4

3. 24 PPI , 98

, 2012 4

4. , 18

2012 6

5. 24 PPI 44

, 2012 8

6. , 33 ,

2012 12

7. IBD

, 83 , 2012 5

193

8.

, 9 2 2013

1

9. NF- B Guggulsterone

, 98 , 2012 4

10. ,

23 , 2012 10

11. SY 3 AKI SY-3-3 AKI

, 57 , 2012 6

22

12. Culture test of H.pylori using gastric juice samples, 18

, 2012 6

13. H. pylori cagA vacA

, 18 , 2012 6

4

1. 18 , 2012 6.

2. 53 , 2012 5

3. 30 , 2012 11

1. :

2. :

3. :

4. :

5. :

6. :

7. :

8.

9. :

10. :

11. CKD Scientific Committee

12. :

13. :

14.

15.

16.

17.

194

18.

19.

20.

21.

22.

23.

24.

0 9

1. :The Open Pathology Journal, Editorial Advisory Board, ,

2. :World Journal of Nephrology, Editorial Board Member, ,

3. :Case Reports in Nephrology Editorial Board Member, ,

4. :Open Journal of Nephrology Editorial Board Member, ,

5. :World Journal of Gastrointestinal Oncology Editorial Board, ,

6. World Journal of Pharmacology Editorial Board, ,

7. World Journal of Clinical Case Conference Editorial Board, ,

8. : World Journal of Nephrology Editorial Board Member

9. Case Report in Nephrology Editorial Board Member

1. 1 Neurology (USA)

2. 1 J Neurol Sci (USA)

3. 1 Neurobiology (USA)

4. 1 Hepatol Res (USA)

5. 2 ISRN Neurology (Korea)

6. 1 PLOS ONE (USA)

7. Kidney Int (USA) 1

8. : Ther Apher Dialysis (Japan) 1

9. : Clinical and Experimental Nephrology (Japan) 3

10. : CEN case reports (Japan) 1

11. : Intern Med (Japan) 1

12. : 4 J Gastroenterology (Japan)

13. : 2 J Med Microbiol (England)

195

14. : 1 Expert Review of Clinical Pharmacology (USA)

15. : 6 Pros One (USA)

16. : 2 Helicobacter (USA)

17. : 4 World J Gastroenterol (China)

18. : 1 Dig Dis Sci (USA)

19. : 1 Digestion (Greece)

20. : 1 Current Microbiology (USA)

21. Clinical Experimental Nephrology (Japan) 2

22. International Journal of Nephrology and Renovascular Disease (USA) 2

23. BMC Nephrology (USA) 1

24. Tohoku Journal of Experimental Medicine (Japan) 1

25. Journal of Public Health and Epidemiology (Republic of Kenya) 1

26. Medical Science Monitor (USA) 1

27. International Journal of Clinical Medicine (USA) 1

28. British Journal of Medicine and Medical Research (UK) 1

24

0

0

0

24

0

1. 2012 11

2. 17 2012 6

3. : 43 2012 10

4. 117 2012 11

196

1.

1987

(1)

(2) 2 3

(3) (4)

(5) GPI

2 3

2

2 GPI

3

1

,

2.

2

Neurodegeneration

with brain iron accumulation disease (NBIA)

Leigh

3.

TGM6 TGM6

2

,

197

4. PET

PET

PET

2013

J neurology

PET ,

,

5. - (RAS) 24

RAS

RAS RAS

RAS

RAS (AGT)

(CKD)

RAS CKD RAS

(UAE)

CKD Riser

(CKD-R) (CKD-NR) CKD-NR RAS UAE

CKD CKD-R RAS UAE

CKD-R RAS

RAS RAS

, ,

6.

S

G1

Flow cytometry Cdt1

G1 G0:G1 3:2 G0:G1

6 1 G1

lead acetate G1

S

G1

, , , ,

198

7.

(P)RR -

RAS RAS

AKI AKI

AKI RAS

AKI PRR

AKI AKI (P)RR RAS

SD 8 45

AKI AKI

24~48 (P)RR AKI

1 ERK1/2 (P)RR

(P)RR AKI ,

, , ,

8. H.pylori esomeprazole omeprazole CYP2C19

PPI CYP2C19 CYP2C19

omeprazole OPZ S

esomeprazole EPZ OPZ CYP2C19

PPI H.pylori

EPZ OPZ CYP2C19 EPZ

40 CYP2C19 rapid metabolizer [RM] 15 intermediated

metabolizer [IM] 15 poor metabolizer [PM] 10 rabeprazole RPZ

lansoplazole LPZ 4 esomeprazole

CYP2C19 RM PPI

, , , ,

9. IL-12 B

IL-12 B (Breg) IL-12 Breg

wild type Th17 IL-17

(Sugimoto et al.Gastroenterology 133,124-136,2007) Breg

Breg

Resting

Treg Activated Treg IL-12 Breg

, , ,

199

10. Sevoflurane TNBS

TNBS Th1

Sevoflurane TNBS

, , ,

1. 2013

1 24

2. 2013 1 25

3. , , 20 2013 3 14

200